Ubiquitin modification in osteogenic differentiation and bone formation: From mechanisms to clinical significance

Yuan Pan1†, Yiman Tang2†, Hang Gu1 and Wenshu Ge1*

1Department of General Dentistry II, Peking University School and Hospital of Stomatology, National Center of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, China, 2Fourth Clinical Division, Peking University School and Hospital of Stomatology, National Center of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, China

The ubiquitin–proteasome system is an important pathway for mediating posttranslational modification and protein homeostasis and exerts a wide range of functions in diverse biological processes, including stem cell differentiation, DNA repair, and cell cycle regulation. Many studies have shown that ubiquitination modification plays a critical role in regulating the osteogenic differentiation of stem cells and bone formation through various mechanisms. This review summarizes current progress on the effects and mechanisms of ubiquitin modification on transcription factors and signaling pathways involved in osteogenic differentiation. Moreover, the review highlights the latest advances in the clinical application of drugs in bone tissue engineering. A thorough understanding of ubiquitin modifications may provide promising therapeutic targets for stem cell-based bone tissue engineering.

KEYWORDS
ubiquitin modification, epigenetics, mesenchymal stem cells, osteogenic differentiation, protein deubiquitinases

1 Introduction

The reconstruction of large bone defects caused by trauma, infection, bone tumor resection, etc., is challenging due to the limited self-repair ability of bone tissue. In recent years, the development of bone tissue engineering has increased the efficiency of bone reconstruction. Mesenchymal stem cells (MSCs) are considered the most promising, because these adult stem cells possess the ability to self-renew and undergo differentiation into diverse cell lineages, such as osteoblasts, adipocytes, and chondrocytes (Squillaro et al., 2016; Lin et al., 2019). However, the molecular mechanism of osteogenic differentiation of MSCs remains unclear, posing a barrier to the further development...
of MSC-based treatment for bone defects. Thus, studies on the regulation of the osteogenic differentiation of MSCs will help identify new targets.

Cell differentiation is determined by genetic and epigenetic mechanisms (Huang et al., 2015). Epigenetic modifications are genetic alterations in gene function without affecting DNA sequence and include DNA methylation, histone modification, and regulation by noncoding RNA (Egger et al., 2004). Recent studies have shown that stemness regulatory factors in conjunction with chromatin remodeling complexes, histone modification, or posttranslational modification of chromatin binding factors play an important role in stem cell fate determination (Orkin and Hochedlinger, 2011; Atlasi and Stunnenberg, 2017). As one of the important protein posttranslational modifications, ubiquitination dynamically regulates protein stability, protein localization, and signal transduction, and thus, affects cell cycle proliferation, apoptosis, and differentiation (Reyes-Turcu and Wilkinson, 2009; Frezza et al., 2011). Ubiquitination is reversible, and deubiquitination is achieved by deubiquitinating enzymes (Suresh et al., 2016). Ubiquitin modification regulates not only proteasome-mediated degradation but also biological processes, such as DNA repair, endocytosis, autophagy, transcription, immunity, and inflammation (Kwon et al., 2017). Understanding ubiquitin modification in the osteogenic differentiation of stem cells is of great clinical significance in orthopedic disease and would advance the development of MSC-based bone tissue engineering.

This review summarizes the role and mechanism of ubiquitin modification in the osteogenic differentiation of stem cells and discusses the latest progress in preclinical studies and future applications. Moreover, this review highlights the recently completed or ongoing clinical trials and discusses the major challenges and use of ubiquitin modification in therapeutic application.

2 Methods

A primary database was established for all relevant articles (February 2001–September 2022) based on the PubMed database. The following keywords and their combinations were used: (ubiquitin OR ubiquitination [Title/Abstract] OR deubiquitin [Title/Abstract] OR deubiquitination [Title/Abstract]) AND (osteogenesis [Title/Abstract] OR osteogenic [Title/Abstract]). Titles and abstracts were selected based on the following criteria:

1) Only original research articles were included.
2) Studies based on ubiquitination in the osteogenic differentiation of MSCs, including the ubiquitin–proteasome system (UPS), ubiquitin ligases, and protein deubiquitinating enzymes, were included.

A total of 219 articles were retrieved after the initial database search, and then 14 reviews were excluded. The titles and abstracts were screened, and 123 articles were excluded because they were not relevant to the current analysis or included letters, editorial, or duplicate reports. Of the 82 potentially relevant studies, 37 were further excluded after the full-text was reviewed, because 29 were not related to ubiquitination-related enzymes and 8 were not related to stem cell osteogenic differentiation. Reference tracking was performed on the full-texts of the resulting articles to identify missing articles that met the inclusion criteria. Four articles fulfilled the inclusion criteria. The final number of included articles was 49 (Figure 1A). The number of articles in this field has steadily increased over the last 2 decades, demonstrating the importance of ubiquitination modification in bone tissue engineering (Figure 1B). Among the included studies, ubiquitin–specific protease (USP) and ubiquitin ligase were the most frequently investigated enzymes that affect stem cell osteogenic differentiation, accounting for more than three-quarters of the total (Figure 1C).

3 Ubiquitinating and deubiquitinating enzymes

Ubiquitin—a highly conserved protein composed of 76 amino acids—binds a protein substrate as a monomer or polymer (Komander and Rape, 2012; Kulathu and Komander, 2012). Ubiquitin contains seven lysine (K) residues: K6, K11, K27, K29, K33, K48, and K63, each of which can form isopeptide bonds with the COOH terminus of other ubiquitin molecules, thereby constituting a polyubiquitin chain. Polyubiquitin chains formed by K48 and K63 chains are the most prevalent ubiquitin chains. Polyubiquitination through K48 guides protein degradation by the 26S proteasome, whereas that through K63 regulates signal transduction and protein activity (Chandrasekaran et al., 2017). In eukaryotes, UPS is one of the most important protein degradation pathways, with high selectivity. UPS mainly degrades misfolded proteins, short-lived proteins, proteins that must be cleared in response to signal-based stimulation, and proteins that must be rapidly degraded by transformation from long-lived proteins. UPS primarily relies on three ubiquitin-related enzymes and protein deubiquitinating enzymes.

Ubiquitination is a three-enzyme cascade reaction involving three enzymes: E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and E3 ubiquitin ligating enzyme. First, E1 activates ubiquitin by linking the C-terminal of ubiquitin to a cysteine residue in E1 through ATP-dependent thioester bond formation. Second, E1 transfers activated ubiquitin to E2. Last, E3 catalyzes ubiquitin transfer from E2 to lysine residues on target proteins. E3 can identify target proteins that must be ubiquitinated.
therefore, the last step occurs in a subunit-specific manner and is highly regulated (Foot et al., 2017). Multiple ubiquitination events lead to the formation of polyubiquitin chains whose lysine or amino terminus can be used to polymerize ubiquitin, thereby amplifying the polyubiquitin signal. Different polyubiquitin chains are associated with varied cellular outcomes (Mevissen and Komander, 2017). Receptors recognize diverse ubiquitin modifications linked to target proteins, resulting in different signaling outputs. These receptors have ubiquitin-binding domains that interact with...
ubiquitin or polyubiquitin, and may also have domains that interact with modified target proteins or other macromolecules.

As with most posttranslational modifications, ubiquitination is reversible. Deubiquitination is accomplished by enzymes collectively known as protein deubiquitinases (DUBs). DUBs are a large family of proteases comprising the catalytic domain, ubiquitin-interacting motif, ubiquitin-associated domain, ubiquitin-binding domain, ubiquitin-like folding domain, and zinc-finger USP domain. These domains facilitate the binding and recognition of different ubiquitin chains. The human genome encodes nearly 100 DUBs, making it the largest family of UPS. DUBs are classified into two major groups: the cysteine protease family and the metalloprotease family (Table 1). (Guo et al., 2018) The enzymatic activity of cysteine proteases is dependent on the sulfhydryl group at the active site and deprotonation of cysteine is assisted by the adjacent histidine, polarized by aspartic acid residues. This family contains USP, ubiquitin C-terminal hydrolases (UCHs), Machado–Josephin domain proteases, and ovarian tumor-related proteases (OTUs). However, the metalloprotease family only contains Jab1/MPN domain-associated metalloisopeptidases (JAMMs), which use Zn2+-bonded polarized water molecules to form noncovalent intermediates with substrates. Metal atoms are mainly stabilized by one aspartic acid and two histidine residues, and the intermediates are further hydrolyzed by proton transfer from water molecules, thus releasing DUBs (Rahman et al., 2015; Mevissen and Komander, 2017).

DUBs hydrolyze ubiquitin molecules on target proteins by hydrolyzing ester, peptide, or isopeptide bonds at the carboxyl terminal of ubiquitin. Additionally, DUBs can process ubiquitin precursors and degrade unbound ubiquitin synthesized de novo or released by other DUBs. Thus, they identify distinct forms of ubiquitin and polyubiquitin, similar to cell-targeted receptors. Deubiquitination is involved in many cellular functions, including DNA repair, protein degradation, cell cycle regulation, stem cell differentiation, and cell signaling. DUBs play a key role in bone tissue engineering by regulating stem cell differentiation and function (Guo et al., 2018).

### 4. Mechanism of ubiquitin modification regulating the osteogenic differentiation of stem cells

Ubiquitin modification regulates many signaling pathways and transcription factors during the osteogenic differentiation of stem cells. The major signaling pathways involve transforming growth factor β (TGF-β)/bone morphogenetic protein (BMP), Wnt/β-catenin, hedgehog, fibroblast growth factor, nuclear factor kappa-B (NF-κB), and parathyroid hormone signaling pathways (Rahman et al., 2015; Fan et al., 2017; Sun et al., 2018). Additionally, ubiquitin modification also plays a vital role in the osteogenic differentiation of stem cells by regulating transcription factors, such as runt-related transcription factor 2 (RUNX2). (Lim et al., 2016) (Figure 2).

### 4.1 Ubiquitin ligase E3

E3 includes the homologous to E6-APC terminus (HECT) domain, RING domain, and U-box domain families of ubiquitin ligases. Some studies have implicated E3 ubiquitin ligases in the regulation of osteogenic differentiation in stem cells. (Shen et al., 2021).

#### 4.1.1 The HECT domain family

The neural precursor cell-expressed developmentally downregulated gene 4 (Ned4), belonging to the HECT domain family, is one of the most studied and understood E3 enzymes. Ned4 includes Smad ubiquitination regulatory factor 1 (Smurf1), Smurf2, WW domain-containing E3 ubiquitin protein ligase 1 (WWP1), WWP2, atrophin-1-interacting protein 4 (or Itch), Ned4, Ned4-like (Ned4L). E3 ubiquitin protein ligase, Ned4-like ubiquitin protein ligase 1 (NED1), and NEDL2. Smurf1—the first ubiquitin ligase implicated in bone formation—regulates osteoblast metabolism by ubiquitinating TGF superfamily proteins Smad (Smad1 and Smad5) and RUNX2 (Ying et al., 2003). Moreover,
Smurf1 was reported to block osteoblast differentiation in various ways. For example, Smurf1 inhibits the c-Jun N-terminal kinase signaling pathway by promoting MAP kinase kinase-2 ubiquitination and degradation, thereby inhibiting osteoblast differentiation (Yamashita et al., 2005). Smurf1 was reported to inhibit osteoblast differentiation by promoting the degradation of the AP-1 family transcription factor JunB (Zhao et al., 2010). Smurf2 induces Smad1/5 ubiquitination and negatively regulates BMP/Smad signaling, thereby inhibiting the osteogenic differentiation of MSCs (Kushioka et al., 2020). Furthermore, WW1 promotes the ubiquitination and degradation of JunB to inhibit osteoblast differentiation (Zhao et al., 2011). WW2 positively regulates osteogenesis by catalyzing the monoubiquitination of RUNX2 and promoting the transactivation of RUNX2 (Zhu et al., 2017). Nedd4 was reported to promote bone formation by activating TGFβ1 signaling to increase osteoblast proliferation (Jeon et al., 2018). Itch, which contains the WW domain, was reported to inhibit osteogenic differentiation (Liu et al., 2017). Nedd4L or RSP5, of the HECT domain family, induces K63-linked ubiquitination of protein kinase B (PKB/AKT), promoting the osteogenic differentiation of MSCs through the AKT signaling pathway (Liang et al., 2020).
4.1.2 Casitas B-lineage lymphoma family

Casitas B-lineage lymphoma (Cbl), an E3 ligase, was reported to negatively regulate osteogenic differentiation. Cbl can reduce the stability and nuclear localization of osterix by inhibiting the phosphoinositide-3-kinase–PKB/AKT pathway, thus inhibiting osteogenic differentiation (Scanlon et al., 2017). According to a study, Cbl reduces the ubiquitination of platelet-derived growth factor receptor and fibroblast growth factor receptor 2 by inhibiting their interaction with receptor tyrosine kinases, thus indicating osteogenic differentiation of MSCs (Severe et al., 2011). Cbl-b and c-Cbl, members of the Cbl family, suppress the osteogenic differentiation of BMP2-induced MSCs and play essential roles in bone formation through an increase in UPS-mediated osterix degradation (Choi et al., 2015). According to a detailed study, c-Cbl mediated the ubiquitination of signal transducers and activators of transcription 5 protein and reduced the expression of insulin-like growth factor 1, thereby inhibiting the osteogenic differentiation of MSCs (Dieudonne et al., 2013).

4.1.3 The U-box domain family

S-phase kinase associated protein 2 of the Skp–Cullin–F-box family negatively regulates osteogenic differentiation by targeting RUNX2 degradation (Thacker et al., 2016). F-box/WD repeat-containing protein 7, another component of the Skp–Cullin–F-box ubiquitin ligase complex, has been shown to negatively regulate osterix protein stability and osteoblast differentiation (Hoshikawa et al., 2020).

4.1.4 Other E3 ligases

In addition to the well-known ubiquitin ligases discussed, other ubiquitin ligases have been implicated in the regulation of osteogenic differentiation. Ring finger protein 185 inhibits the WNT signaling pathway by promoting the ubiquitination and degradation of Dvl2, thus negatively regulating osteogenic differentiation (Zhou et al., 2014). Tripartite motif (TRIM) 16 was found to stabilize RUNX2 by reducing the CHIP-mediated ubiquitination and degradation of K48-linked RUNX2, thereby promoting the osteogenic differentiation of human periodontal ligament stem cells (Zhao et al., 2020). TRIM21 was reported to promote the K48-linked ubiquitination of AKT, which accelerated the degradation of AKT to inhibit the osteotropic signaling pathway, thus inhibiting the osteogenic differentiation of MSCs (Xian et al., 2022). The cell division cycle 20 protein promotes P65 degradation in an anaphase-promoting complex subunit 1-dependent manner, which in turn promotes osteogenic differentiation (Du et al., 2021). The ubiquitin ligase TNF receptor-associated factor (TRAF)4 positively regulates the osteogenic differentiation of MSCs by mediating the K48-linked ubiquitination and degradation of Smurf2 at K119 (Li et al., 2019). The roles and

| Enzyme | Pathway | Substrate | Function | Author, year, reference |
|--------|---------|-----------|----------|-------------------------|
| Smurf1 | RUNX2   |           | Inhibit  | Ying et al. (2003)      |
|        | TGF-β/BMP | Smad5     | Inhibit  | Ying et al. (2003)      |
|        | JNK     | MEKK      | Inhibit  | Yamashita et al. (2005) |
|        | JunB    |           | Inhibit  | Zhao et al. (2010)      |
| Smurf2 | TGF-β/BMP | Smad1/5   | Inhibit  | Kushieka et al. (2020)  |
| WWP1   | TNF     | JunB      | Inhibit  | Zhao et al. (2011)      |
| WWP2   | RUNX2   |           | Promote  | Zhu et al. (2017)       |
| NEDD4  | TGF-β   | Smad1/2   | Promote  | Jeon et al. (2018)      |
| Itch   | NF-κB   | RelA/RelB | Inhibit  | Liu et al. (2017)       |
| RSP5   | AKT     | PKB       | Promote  | Liang et al. (2020)     |
| Cbl    | Osterix | P13K/AKT  | Inhibit  | Scanlon et al. (2017)   |
|        | ERK1/2 ,P13K | PDGFR, FGR2 | Inhibit | Severe et al. (2011)    |
|        | BMP2    |           | Inhibit  | Choi et al. (2015)      |
|        | RUNX2   | STAT5     | Inhibit  | Diesdorne et al. (2013) |
| Skp2   | RUNX2   |           | Inhibit  | Thacker et al. (2016)   |
| Fbw7   | Ox      |           | Inhibit  | Hoshikawa et al. (2020) |
| Rnf035 | Wnt/β-catenin | Dvl2  | Inhibit  | Zhou et al. (2014)      |
| TRIM16 | RUNX2   | Chip      | Promote  | Zhao et al. (2020)      |
| TRIM21 | AKT     |           | Inhibit  | Xian et al. (2022)      |
| CDC20  | p65     | APC11     | Promote  | Du et al. (2021)        |
| TRAF4  | Smurf2  |           | Promote  | Li et al. (2019)        |
mechanisms of E3 ubiquitin ligases on the osteogenic differentiation of stem cells are summarized in Table 2.

4.2 DUBs

4.2.1 The USP family

The USP family is the largest and most diverse family of DUBs, with 56 members in humans. The catalytic domain of USP is composed of six conserved motifs, of which two are named Cys- and His-box. (Guo et al., 2018).

USP4, USP11, and USP15 share highly similar domains and protein sequences. TGF-β/BMP signaling plays a key role in the osteogenic differentiation of MSCs and bone formation. USP4, USP11, and USP15 act on type I TGF-β receptors (TβRI) (Garg et al., 2017). USP4 can enhance TGF-β signaling by directly interacting with TβRI/ALK5. USP4 is phosphorylated by AKT and translocated to the cytoplasm and membrane, where USP4 binds TβRI to deubiquitinate and protect it from damage (Zhang et al., 2012). Moreover, USP4 stabilizes Smad4 and activates BMP signaling by inhibiting Smad4 monoubiquitination (Zhou et al., 2017). According to a study, USP4 activates Wnt signaling by deubiquitinating and stabilizing β-catenin (Yun et al., 2015). By contrast, USP4 was reported to inhibit Wnt signaling by deubiquitinating the polyubiquitin chains on dishevelled (Dvl/Dsh) and blocking Wnt3a-induced osteoblast differentiation and bone formation (Zhou et al., 2016). Additionally, USP11 promotes the osteogenic differentiation of MSCs by interacting and deubiquitinating Msh homeobox 1 (Kaushal et al., 2022).

USP9X deubiquitinates Smad4 at K519, which inhibits transcription by preventing its binding to phosphorylated Smad2/3. Thus, USP9X activates TGF-β signaling by antagonizing Smad4 monoubiquitination (Dupont et al., 2009). In addition, USP9X-mediated deubiquitination of dishevelled protein 2 (Dvl2) is necessary for canonical Wnt activation (Nielsen et al., 2019). A study has shown that USP34 promotes osteogenic differentiation by activating Smad1/5/8 and stabilizing the transcription factor RUNX2 (Guo et al., 2020).

USP8 promotes osteogenic differentiation by blocking the ubiquitination of Wnt receptor frizzled 5 (FZD5) to stabilize the Wnt/β-catenin signaling pathway (Chaugule et al., 2021). USP53 inhibits proteosome degradation of β-catenin by interacting with F-box only protein 31 (FBXO31), thereby promoting osteogenic differentiation of human bone marrow-derived MSCs (Sack et al., 2021). According to Tang, USP7 can promote the osteogenic differentiation of MSCs through its deubiquitinating activity (Tang et al., 2017). Moreover, USP7 was reported to activate the Wnt/β-catenin signaling pathway by interacting directly with β-catenin (Zeng et al., 2019). USP26 promotes the osteogenic differentiation of MSCs by stabilizing β-catenin and impairs the osteoclastic differentiation of bone myelomonocytes (BMMs) by stabilizing inhibitors of NF-κB (Li et al., 2022).

Studies on USP42 suggest that USP42 regulates transcription by binding to and deubiquitinating histone H2B (Hock et al., 2014). USP42 was reported to negatively regulate Wnt/β-catenin signaling and promote the clearance of the Wnt receptor (Giebel et al., 2021), suggesting that USP42 is involved in the regulation of stem cell differentiation.

4.2.2 The UCH family

The UCH family members contain an N-terminal catalytic domain of 230 residues, frequently followed by C-terminal extensions that mediate protein–protein interactions. The four human UCHs are divided into smaller UCHs (UCH-L1 and UCH-L3) and larger UCHs (UCH37/UCH-L5, and BAP1) based on substrate specificity (Eletr and Wilkinson, 2014). UCH-L3 activates osteoblast differentiation by deubiquitinating and stabilizing Smad1 (Kim et al., 2011). Moreover, UCH-L3 was reported to activate NF-κB signaling by deubiquitinating and stabilizing the ubiquitin ligase TRAF2 (Zhang et al., 2020).

4.2.3 The OUT family

The OTU family is identified according to their homology with ovarian tumor genes. A total of 15 genes in the human genome are grouped into three subclasses: OTUB, OTU, and A20-like OTU (Eletr and Wilkinson, 2014). A20 recruited by Smad6 inhibits the TGF-β1-induced, K63-linked polyubiquitination of TRAF6 and contributes to the negative regulation of nonstandard TGF-β signaling (Jung et al., 2013), suggesting that A20 regulates osteogenic differentiation through this primary pathway. OTUB1 inhibits the ubiquitination of phospho-SMAD2/3 by binding to and inhibiting E2, independent of its catalytic activity, thereby activating TGF-β signaling (Herhaus et al., 2013). Other studies have shown that OTUB2 regulates hedgehog signaling by inhibiting the degradation of transcription factor Gli2, thereby promoting osteogenic differentiation (Li et al., 2018).

4.2.4 Machado–Josephin domain proteases MJDs

The Machado–Josephin domain proteases family has four members, which contain the catalytic triad domains formed by two highly conserved histidine boxes and one cysteine box (Eletr and Wilkinson, 2014). However, studies on the relationship between Josephin-Dubs and the osteogenic differentiation of stem cells are lacking.

4.2.5 JAMM domain proteins

Humans possess eight JAMMs domain proteins in humans (Eletr and Wilkinson, 2014). MYSM1, a member of the JAMMs family, has been shown to affect the maturation and differentiation of osteoblasts (Haffner-Luntzer et al., 2018);
however, its effect on osteogenic differentiation of stem cells has not been reported.

Table 3 summarizes the mechanisms and effects of DUBs on the osteogenic differentiation of MSCs.

Ubiquitination and deubiquitination regulate osteogenic differentiation of stem cells through multiple pathways. If specific ubiquitin-related enzymes that regulate osteogenic differentiation can be systematically screened out, it is expected to participate in the regulation of stem cells fate through overexpression or inhibition of a series of enzymes. Therefore, mapping the interaction between ubiquitination and deubiquitination in the stem cell regulatory network may have a significant impact on tissue engineering and translational medicine research.

5 Application of ubiquitin modification in bone tissue engineering

In recent years, the use of UPS as a new target for disease treatment has gradually attracted people’s attention. Bortezomib was the first proteasome inhibitor to be approved for use in the treatment of multiple myeloma (Oyajobi et al., 2007). Bortezomib is believed to treat postmenopausal osteoporosis by suppressing Smurf-mediated SMAD ubiquitination (Fang et al., 2021). In clinical studies, bortezomib was reported to increase the proliferation and differentiation of osteoblasts by increasing β-catenin levels (Qiang et al., 2009). Treatment of mice with low doses of bortezomib (approximately one-fifth to one-third the dose equivalent required for the antitumor effect) increased bone formation and mineralized trabecular bone (Mukherjee et al., 2008). This strategy may be used to increase bone volume in malignant osteolytic disease or osteoporosis. Another proteasome inhibitor, withaferin A, was reported to promote fracture healing and regulate bone anabolism in osteoporosis (Khedgikar et al., 2013). In addition, local injection of the proteasome inhibitor PS1 and cyclooxygenin promoted fracture healing in rats (Yoshii et al., 2015). Melatonin is a type of indolamine with many biological functions. Melatonin was reported to promote bone formation through the BMP/MAPK/Wnt signaling pathway (Luchetti et al., 2014). Moreover, melatonin reversed TNFα-mediated inhibition of osteogenesis in MSCs by stabilizing Smad1 and is a promising therapeutic agent for TNFα-mediated inhibition of osteogenesis (Lian et al., 2016). The developments in tissue engineering have made stem cell transplantation feasible for treating bone-related diseases, such as osteoporosis. In the transplantation process, pretreatment of cells with ubiquitin-related enzymes and their small molecule inhibitors increases osteogenic differentiation. The proteasome inhibitor lactacystin accelerated BMP-induced osteogenic
differentiation by increasing the levels of phosphorylated Smad proteins. Optimized lactacystin treatment in a clinical setting may facilitate autogenous or BMP-induced bone formation in bones with defects (Ito et al., 2011). In addition, osteocytes also play an important role in bone remodeling (Currey et al., 2017). Osteocytes produce proteins, including receptor activator of NF-κB ligand (RANKL) and sclerostin, which contribute to both bone resorption and formation. RANKL is essential for osteoclast formation, and sclerostin inhibits canonical Wnt signaling required for osteoblast differentiation (Li et al., 2005; Xiong et al., 2015). Damaged osteocytes repair themselves through autophagy. Some evidence suggests that inhibiting autophagy in osteocytes promotes osteocyte death as well as some aging-associated bone changes. However, if osteocyte injury is severe, autophagy cannot repair the damage, and osteocyte apoptosis is induced. Local osteocyte apoptosis increases RANKL levels in surrounding osteocytes, which results in an increase in osteoclasts (Jilka and O’Brien, 2016). A study showed that casein kinase 2-induced phosphorylation of USP4 stabilizes sirtuin1 by inhibiting ubiquitin-dependent proteasomal degradation. Upregulation of sirtuin1 inhibited sclerostin transcription in osteocytes, which is essential for maintaining bone homeostasis (Kim et al., 2022).

Recent animal-based studies have reported the significance of ubiquitin modification-related enzymes and their inhibitors or activators in bone tissue engineering. The inhibitor of USP7 activity HBX 41108 blocks the osteogenic differentiation of hMSCs (Tang et al., 2017). In a study, the loss of USP34 in MSCs impaired fixation of mouse titanium implants. Thus, USP34 is an important drug target for promoting the osteogenic differentiation of stem cells (Xue et al., 2020). RTA-408, an activator of nuclear factor-erythroid 2-related factor 2, was reported to inhibit osteoclast formation in vitro. In this study, the researchers established a model of oophorectomy-induced osteoporosis, demonstrating that RTA-408 inhibited NF-κB signaling by suppressing the recruitment of TRAF6 to stimulator of interferon genes protein (Sun et al., 2020). Another study demonstrated that oltipraz, an activator of nuclear factor-erythroid 2-related factor 2, rescued the osteoporotic phenotype induced by 1,25(OH)2D deficiency in male mice. Thus, oltipraz can potentially be used for the clinical prevention and treatment of age-related osteoporosis (Yang et al., 2022).

Although several studies have proved the involvement of ubiquitin modification in osteogenic differentiation and bone formation, the clinical use of drugs is limited due to drawbacks, such as low specificity and undesirable dose-dependent side-effects. To overcome the dose-dependent side-effects of high-dose BMP, researchers developed GapmeRs, which are a type of LNA-ASOs with enhanced stability that are clinically safe to modify MSC gene expression, and a non-toxic lipid transport system for Smurf1 silencing. Smurf1 silencing combined with the long-term release of low doses of BMP2 from a biocompatible scaffold promoted bone formation in vivo. The findings of this study provide a great possibility for the clinical application of ubiquitination modification in promoting bone formation (Garcia-Garcia et al., 2019).

Many challenges exist in clinically applying the findings of ubiquitination studies. First, many studies have developed small molecule inhibitors that target DUBs; however, screening small molecule compounds has been challenging for pharmaceutical companies due to the unique differences in the three-dimensional structures of the catalytic sites of DUBs. Second, the application of small molecule drugs requires the identification of candidate stem cell populations to improve drug specificity for bone tissue. Simultaneously, the safety of the drug to other tissues must be ascertained. In addition, because the bioavailability of drugs is usually not high, the dose-dependent side-effects of the drugs must be assessed.

### 6 Perspectives and challenges

Because many components of UPS are involved in the regulation of stem cell differentiation, understanding the biochemical roles of ubiquitination modification pathways is critical. Although different family members of UPS have similar catalytic activity centers, they regulate gene expression differentially because of variations in their structure and function. Many types of substrate proteins are targeted by UPS. The enzymes that target transcription factors, cell cycle regulators, and damage repair factors need to be identified and studied. However, studies on regulators of enzyme activity and spatiotemporal specificity during ubiquitination have higher application value than the study of substrates themselves. Therefore, UPS is an attractive drug target. Screening of small molecule inhibitors and developing drugs that target UPS will be a hot topic for future research.

The following research directions are worth discussing. First, new DUBs should be identified, and a gold standard for the characterization of deubiquitinating enzyme should be established. Comparative genomics and proteomics should be used to screen and classify deubiquitinating enzymes. Second, our understanding of UPS function is limited. Therefore, the physiological functions of UPS enzymes, such as their catalytic activity, substrate specificity, and regulation, must be studied to evaluate the critical factors involved in and regulatory
networks of UPS. Finally, many studies have shown that the regulation of UPS can bring new ideas for the treatment of various diseases including tumors, but current studies mostly rely on the cellular level and animal level. Systematic and comprehensive clinical studies and verification of the in vivo effects of UPS are urgently needed.

In conclusion, ubiquitin modification regulates osteogenic differentiation of stem cells. The development of bone tissue engineering and MSC-based therapies will benefit from a better understanding of the effects and molecular mechanisms of ubiquitination on the osteogenic differentiation of stem cells.

Author contributions

YP and YT performed the literature search and wrote the manuscript. HG performed the literature search and revised the manuscript. WG conceived the review, revised the manuscript, and provided final approval of the manuscript and financial support. All authors read and approved the final version of the manuscript.

References

Atalay, Y., and Stunnenberg, H. G. (2017). The interplay of epigenetic marks during stem cell differentiation and development. Nat. Rev. Genet. 18 (11), 643–658. doi:10.1038/nrg.2017.57

Baek, D., Park, K. H., Lee, K. M., Jung, S., Jong, S., Kim, J., et al. (2021). Ubiquitin-specific protease 53 promotes osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Cell Death Dis. 12 (3), 238. doi:10.1038/s41419-021-03517-x

Chandrasekaran, A. P., Suresh, B., Kim, H. H., Kim, K. S., and Ramakrishna, S. (2017). Concise review: Fate determination of stem cells by deubiquitinating enzymes. Stem Cells 35 (1), 9–16. doi:10.1002/stem.2446

Changule, S., Kim, J. M., Yang, Y. S., Knoblech, K. P., He, X., and Shim, J. H. (2021). Deubiquitinating enzyme USP8 is essential for skeletogenesis by regulating Wnt signaling. Int. J. Mol. Sci. 22 (19), 10289. doi:10.3390/ijms221910289

Choi, Y. H., Han, Y., Lee, S. H., Jin, Y. H., Bahn, M., Hur, K. C., et al. (2015). Cbl-b and c-Cbl negatively regulate osteoblast differentiation by enhancing ubiquitination and degradation of Osterix. Bone 75, 201–209. doi:10.1016/j.bone.2015.02.057

Currey, J. D., Dean, M. N., and Shahar, R. (2017). Revisiting the links between bone remodelling and osteocytes: Insights from across phyla. Biol. Rev. Camb. Philos. Soc. 92 (3), 1702–1719. doi:10.1111/brv.12302

Dieudonne, F. X., Severe, N., Bisoue-Duplan, M., Wong, J. J., Su, Y., and Mare, P. J. (2013). Promotion of osteoblast differentiation in mesenchymal cells through cbl-mediated control of STAT5 activity. Stem Cells 31 (7), 1340–1349. doi:10.1002/stem.1386

Du, Y., Zhang, M., Liu, X., Li, Z., Hu, M., Tian, Y., et al. (2021). CDC20 promotes bone formation via APC/C dependent ubiquitination and degradation of p65. EMBO Rep. 22 (9), e52576. doi:10.15252/embr.2021252576

Dupont, S., Mamiadi, A., Cordenonsi, M., Montaguer, M., Zacchigna, L., Adorno, M., et al. (2009). FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136 (1), 123–135. doi:10.1016/j.cell.2008.10.051

Egger, G., Li, A., Pannier, A., and Jones, P. A. (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (6990), 457–463. doi:10.1038/nature02625

Eliot, Z. M., and Wilkinson, K. D. (2014). Regulation of proteolysis by human deubiquitinating enzymes. Biochim. Biophys. Acta 1843 (1), 114–128. doi:10.1016/j.bbamcr.2013.06.027

Fang, Y., Liu, Y., Zhao, Z., Lu, Y., Shen, X., Zhu, T., et al. (2021). Bortezomib rescues ovariectomy-induced bone loss via SMURF-mediated ubiquitination pathway. Oxid. Med. Cell. Longev. 2021, 9661200. doi:10.1155/2021/9661200

Foot, N., Henshall, T., and Kumar, S. (2017). Ubiquitination and the regulation of membrane proteins. Physiol. Rev. 97 (1), 253–281. doi:10.1152/physrev.00012.2016

Frezza, M., Schmitt, S., and Dou, P. Q. (2011). Targeting the ubiquitin-proteasome pathway: An emerging concept in cancer therapy. Curr. Top. Med. Chem. 11 (23), 2888–2905. doi:10.2174/156802611798281311

Garcia-Garcia, P., Ruiz, M., Reyes, R., Delgado, A., Evora, C., Biancho, J. A., et al. (2019). Smurf1 silencing using a LNA-ASO5/lipid nanoparticle system to promote bone regeneration. Stem Cells Transl. Med. 8 (12), 1306–1317. doi:10.1002/stem.19045

Garg, P., Mazur, M. M., Buck, A. C., Wandtke, M. E., Liu, J. Y., and Ebraheim, N. A. (2017). Prospective review of mesenchymal stem cells differentiation into osteoblasts. Orthop. Surg. 9 (1), 13–19. doi:10.1111/os.12304

Giebel, N., de Jaime-Seguero, A., Garcia Del Arco, A., Landry, J. M., Tietje, M., Villacorta, L., et al. (2021). USP42 protects ZNF3E/RNF43 from R-spondin-dependent clearance and inhibits Wnt signalling. EMBO Rep. 22 (5), e51415. doi:10.15252/embr.202021415

Guo, Y. C., Yang, M. Y., Zang, S. W., Wu, Y. S., Zhou, C. C., Zheng, R. X., et al. (2020). Ubiquitin-specific protease USP34 controls osteogenic differentiation and bone formation by regulating BMP2 signalling. EMBO J. 39 (20), e99398. doi:10.15252/embj.201899398

Guo, Y. C., Zang, S. W., and Yuan, Q. (2018). Deubiquitinating enzymes and bone remodeling. Stem Cells Int. 2018, 3712083. doi:10.1155/2018/3712083

Haffner-Lunert, M., Kottwitz, A., Fischer, V., Przysta, K., Hainzl, A., Kroeger, C. M., et al. (2018). Loss of p53 compensates osteopenia in murine Mysm1 deiciency. FASEB J. 32 (4), 1597–1608. doi:10.1096/fj.201700871R

Herhausen, L., Al-Sailhi, M., Macartney, T., Wiedlich, S., and Sapkota, G. P. (2013). OTUB1 enhances TGF beta signalling by inhibiting the ubiquitlation and degradation of active SMAD2/3. Nat. Commun. 4, 2519. doi:10.1038/ncomms3519

Hock, A. K., Vigneron, A. M., and Vouden, K. H. (2014). Ubiquitin-specific peptidase 42 (USP42) functions to deubiquitylate histones and regulate

Funding

This study was supported by grants from the National Natural Science Foundation of China (No. 82071089 to WG), and the National Natural Science Foundation of China (No. 82001013 to YT).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
transcriptional activity. *J. Biol. Chem.* 289 (50), 34862–34870. doi:10.1074/jbc.M111.589267

Hoshikawa, S., Šimizu, K., Watahiki, A., Chiba, M., Saito, K., Wei, W., et al. (2020). Phosphorylation-dependent osteostatin degradation negatively regulates osteoblast differentiation. *Nat. Protoc.* 15 (3), 1493–14945. doi:10.1038/s41596-2020-3408R

Huang, B., Li, G., and Jiang, X. H. (2015). Fate determination in mesenchymal stem cells: A perspective from histone-modifying enzymes. *Stem Cell Res. Ther.* 6, 35. doi:10.1186/s13287-015-0018-0

Ito, Y., Fukushima, H., Katagiri, T., Seo, Y., Hirata, S., Zhang, M., et al. (2011). Lacactyvin, a proteasome inhibitor, enhances BMP-induced osteoblastic differentiation by increasing active Smads. *Biochem. Biophys. Res. Commun.* 407 (1), 225–229. doi:10.1016/j.bbrc.2011.03.003

Jeon, S. A., Lee, J. H., Kim, D. W., and Cho, J. Y. (2018). E3-ubiquitin ligase NEDD4 enhances bone formation by removing TGFβ1-induced pSMAD1 in immature osteoblasts. *J. Biol. Chem.* 293 (18), 1121–1126. doi:10.1074/jbc.M117.820586

Kim, J. M., Yang, Y. S., Xie, J., Lee, O., Kim, J., Hong, J., et al. (2022). Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes. *Biochim. Biophys. Acta. Gen. Subj.* 1880 (3), 3462–3470. doi:10.1016/j.bbagen.2019.1089. doi:10.1016/j.celrep.2019.06.083

Orkin, S. H., and Hochengelder, K. (2011). Chromatin connections to pluripotency and cellular reprogramming. *Cell* 145 (6), 835–858. doi:10.1016/j.cell.2011.05.019

Ozawa, B. O., Garrett, I. R., Gupta, A., Flores, A., Esparrazu, J., Munoz, S., et al. (2007). Stimulation of new bone formation by the proteasome inhibitor, bortezomib: Implications for myeloma bone disease. *Br. J. Haematol.* 139 (3), 434–438. doi:10.1111/j.1365-2141.2007.06288.x

Qiang, Y. W., Hu, B., Chen, Y., Zhong, Y., Shi, B., Barlogie, B., et al. (2009). Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TGF signaling. *Blood* 113 (18), 4319–4330. doi:10.1182/blood-2008-08-174300

Rahman, M. S., Akhtar, N., Jamil, H. M., Banik, R. S., and Assaadzaman, S. M. (2015). TGF-β/BMP signaling and other molecular events Regulation of osteoblastogenesis and bone formation. *Bone* 83, 10505. doi:10.1016/j.bone.2015.5

Reyes-Turcu, F. E., and Wilkinson, K. D. (2009). Polyubiquitin binding and disassembly by deubiquitinating enzymes. *Chem. Rev.* 109 (4), 1495–1508. doi:10.1021/cr8004707

Scalan, V., Waila, B., Yu, J., Hansen, M., Drissi, H., Maye, P., et al. (2017). Loss of Chl-Pi3K interaction modulates the peristomal response to fracture by enhancing osteogenic commitment and differentiation. *Bone* 95, 124–135. doi:10.1016/j.bone.2016.11.020

Severe, N., Mirauz, H., and Marie, P. J. (2011). The Casitas B lineage lymphoma (Cbl) mutant G386E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination. *J. Biol. Chem.* 286 (27), 24443–24450. doi:10.1074/jbc.M110.197525

Shen, J., Fu, B., Li, Y., Wu, Y., Sang, H., Zhang, H., et al. (2021). E3 ubiquitin ligase-mediated regulation of osteoblast differentiation and bone formation. *Front. Cell Dev. Biol.* 9, 706395. doi:10.3389/fcel.2021.706395

Squillaro, T., Peluso, G., and Galderisi, U. (2016). Clinical trials with mesenchymal stem cells: An update. *Cell Transpl.* 25 (5), 829–848. doi:10.3727/096368915X698622

Sun, X., Xie, Z., Hu, B., Zhang, B., Ma, Y., Pan, X., et al. (2020). The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-kb signaling. *Redox Biol.* 28, 101309. doi:10.1016/j.redox.2019.101309

Sun, X., Xie, Z., Ma, Y., Pan, X., Wang, J., Chen, Z., et al. (2019). TGF-β inhibits osteogenesis by upregulating the expression of ubiquitin ligase SMURF1 via MAPK-ERK signaling. *J. Cell. Physiol.* 233 (1), 596–606. doi:10.1002/jcp.25920

Suresh, B., Lee, J., Kim, H., and Ramakrishna, S. (2016). Regulation of pluripotency and differentiation by deubiquitinating enzymes. *Stem Cell Dev.* 23 (8), 1267–1268. doi:10.1007/s10863-016-5231-5

Tang, Y. M., Li, L. W., Li, W. Y., Zhang, X., Jiang, Y., Ge, W. S., et al. (2017). Protein deubiquitinating USP17 is required for osteogenic differentiation of human adipose-derived stem cells. *Stem Cell Res. Ther.* 8, 186. doi:10.1186/s13287-017-0637-8

Thacker, G., Kumar, Y., Khan, M. P., Shukla, N., Kapoor, I., Kanaujiya, J. K., et al. (2016). Sm2 inhibits osteogenesis by promoting ubiquitin-proteasome degradation of Runx2. *Biochem. Biophys. Acta* 1863 (6), 510–519. doi:10.1016/j.bbamcr.2016.01.010

Wei, Y., Fu, J. Y., Wu, J. W., Ma, P. F., Ren, L., and Wu, J. H. (2021). Estrogen prevents cell senescence and bone loss through up10-dependent p53 degradation in osteocytes and osteoblasts: The role of estrogen in bone senescence. *Cell Tissue Res.* 386 (2), 297–308. doi:10.1007/s00441-021-03496-7

Liu, J., Li, X., Zhang, H., Gu, R., Wang, Z., Gao, Z., et al. (2017). Ubiquitin E3 ligase Itch negatively regulates osteoblast function by promoting proteasome degradation of osteogenic proteins. *Bone* 106 (5), 154–161. doi:10.1016/j.bone.2016.09.075.BMBR.2016.02.037.R1

Luchetti, F., Canonic, B., Bartolini, D., Arcangeletti, M., Cifidelli, S., Murdolo, G., et al. (2014). Melatonin regulates mesenchymal stem cell differentiation: A review. *J. Pineal Res.* 56 (4), 382–397. doi:10.1111/jprr.12133

Mervissen, T. E. T., and Komander, D. (2017). Mechanisms of deubiquitase specificity and regulation. *Annu. Rev. Biochem.* 86, 159–192. doi:10.1146/annurev-biochem-061516-044916

Mukherjee, S., Raje, N., Sookmaan, J. A., Liu, J. C., Hideshima, T., Weh, M. N., et al. (2008). Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. *J. Clin. Invest.* 118 (2), 491–504. doi:10.1172/JCI313102

Nielsen, C. P., Jernang, K. D., Biggs, D. J., and MacGurn, J. A. (2019). USP15X deubiquitilizes DVL2 to regulate WNT pathway specification. *Cell Rep.* 28 (4), 1074–1089. doi:10.1016/j.celrep.2019.06.083

Park et al. 10.3389/fcell.2022.1033223

Frontiers in Cell and Developmental Biology frontiersin.org
Xian, J., Liang, D., Zhao, C., Chen, Y., and Zhu, Q. (2022). TRIM21 inhibits the osteogenic differentiation of mesenchymal stem cells by facilitating K48 ubiquitination-mediated degradation of Akt. Exp. Cell Res. 412 (2), 113034. doi:10.1016/j.yexcr.2022.113034

Xiong, J., Piemontese, M., Onal, M., Campbell, J., Goellner, J. J., Dusereich, V., et al. (2015). Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. F1000Res 10 (9), e138199. doi:10.12688/journal.pone.0138199

Xue, H., Guo, Y., Zhang, S., Xu, W., Wen, J., Kang, N., et al. (2020). The role of USP34 in the fixation of titanium implants in murine models. Eur. J. Oral Sci. 128 (3), 211–217. doi:10.1111/eos.12696

Yamashita, M., Ying, S. X., Zhang, G. M., Li, C., Cheng, S. Y., Deng, C. X., et al. (2005). Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 121 (1), 101–115. doi:10.1016/j.cell.2005.01.035

Yang, R., Zhang, J., Li, J., Qin, R., Chen, J., Wang, R., et al. (2022). Inhibition of Nrf2 degradation alleviates age-related osteoporosis induced by 1, 25-Dihydroxyvitamin D deficiency. Free Radi. Biol. Med. 178, 246–261. doi:10.1016/j.freeradbiomed.2021.12.010

Ying, S. X., Hussain, Z. J., and Zhang, Y. E. (2003). Smurf1 facilitates myogenic differentiation and antagonizes the bone morphogenetic protein-2-induced osteoblast conversion by targeting Smad5 for degradation. J. Biol. Chem. 278 (40), 39629–39636. doi:10.1074/jbc.M301193200

Yoshii, T., Nyman, J. S., Yuasa, M., Esparza, J. M., Okawa, A., and Gutiérrez, G. E. (2015). Local application of a proteasome inhibitor enhances fracture healing in rats. J. Orthop. Res. 33 (8), 1197–1204. doi:10.1002/jor.22849

Yun, S. I., Kim, H. H., Yoon, J. H., Park, W. S., Hahn, M. J., Kim, H. C., et al. (2015). Ubiquitin specific protease 4 positively regulates the WNT/β-catenin signaling in colorectal cancer. Mol. Oncol. 9 (9), 1834–1851. doi:10.1016/j.molonc.2015.06.006

Zeng, Q., Li, Z., Zhao, X., Guo, L., Yu, C., Qin, Y., et al. (2019). Ubiquitin-specific protease 7 promotes osteosarcoma cell metastasis by inducing epithelial-mesenchymal transition. Oncol. Rep. 41 (1), 543–551. doi:10.3892/or.2018.6835

Zhang, L., Zhou, F. F., Drabsch, Y., Gao, R., Snaar-Jagalska, B. E., Mickanin, C., et al. (2012). USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-beta type I receptor. Nat. Cell Biol. 14 (7), 717–726. doi:10.1038/ncl.2522

Zhang, M. H., Zhang, H. H., Du, X. H., Gao, J., Li, C., Shi, H. R., et al. (2020). UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-kB pathway. Oncogene 39 (2), 322–333. doi:10.1038/s41388-019-0987-z

Zhao, J., Huang, J., Zhang, H. W., Wang, Y., Matesic, I. E., Takahata, M., et al. (2011). Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells 29 (10), 1601–1610. doi:10.1002/stem.703

Zhao, L., Huang, J. A., Guo, R. L., Wang, Y., Chen, D., and Xing, L. P. (2010). Smurf1 inhibits mesenchymal stem cell proliferation and differentiation into osteoblasts through JunB degradation. J. Bone Min. Res. 25 (6), 1246–1256. doi:10.1002/jbmr.28

Zhao, Y., Zhai, Q., Liu, H., Xi, X., Chen, S., and Liu, D. (2020). TRIM16 promotes osteogenic differentiation of human periodontal ligament stem cells by modulating CHIP-mediated degradation of RUNX2. Front. Cell Dev. Biol. 8, 625105. doi:10.3389/fcell.2020.625105

Zhou, F. F., Xie, F., Jin, K., Zhang, Z., Clerici, M., Gao, R., et al. (2017). USP4 inhibits SMAD4 monoubiquitination and promotes activin and BMP signaling. EMBO J. 36 (11), 1623–1639. doi:10.15252/embj.201695372

Zhou, F. F., Li, F., Fang, P. F., Dai, T., Yang, B., van Dam, H., et al. (2016). Ubiquitin-specific protease 4 antagonizes osteoblast differentiation through dishevelled. J. Bone Min. Res. 31 (10), 1888–1898. doi:10.1002/jbmr.2863

Zhou, Y., Shang, H., Zhang, C., Liu, Y., Zhao, Y., Shuang, F., et al. (2014). The E3 ligase RNF185 negatively regulates osteogenic differentiation by targeting Dvl2 for degradation. Biochem. Biophys. Res. Commun. 447 (3), 431–436. doi:10.1016/j.bbrc.2014.04.005

Zhu, W., He, X. Y., Hua, Y., Li, Q., Wang, J. Y., and Gan, X. Q. (2017). The E3 ubiquitin ligase WWP2 facilitates RUNX2 protein transactivation in a mono-ubiquitination manner during osteogenic differentiation. J. Biol. Chem. 292 (27), 11178–11188. doi:10.1074/jbc.M116.772277